Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -41.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 16.32 | 11.90 | 13.62 | 28.79 | 35.23 | 53.48 | 44.34 | 37.16 | 29.58 | 33.94 | 28.68 | 13.34 | 13.40 | 11.41 | 9.40 | 8.91 | 11.18 | 9.60 | 9.04 | 13.16 | 14.38 |
| — | -77.7% | -69.3% | -22.5% | +19.1% | +57.6% | +54.6% | +178.6% | +120.7% | +197.5% | +205.3% | +49.6% | +19.9% | +18.8% | +3.9% | -32.3% | -22.3% | -44.3% | -47.4% | -39.7% | -30.1% | |
| P/B Ratio | 33.08 | 34.39 | 30.59 | 49.99 | 50.31 | 32.20 | 15.24 | 139.15 | 43.31 | 26.23 | 267.02 | — | — | — | — | — | 30.14 | — | 53.31 | 23.31 | 7.86 |
| — | +6.8% | +100.7% | -64.1% | +16.2% | +22.8% | -94.3% | — | — | — | — | — | — | — | — | — | +283.3% | — | +807.8% | +33.9% | -36.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 1563.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 651.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.4% | 85.1% | 84.2% | 83.8% | 83.2% | 79.4% | 73.9% | 77.1% | 75.0% | 77.3% | 76.8% | 76.9% | 78.0% | 78.9% | 78.5% | 78.8% | 78.0% | 80.1% | 74.9% | 77.0% | 76.3% |
| — | +7.2% | +14.0% | +8.8% | +11.0% | +2.6% | -3.8% | +0.3% | -3.9% | -1.9% | -2.2% | -2.4% | +0.0% | -1.5% | +4.9% | +2.3% | +2.1% | +2.4% | -1.6% | +2.0% | +3.5% | |
| Operating Margin | -194.0% | -17.0% | -0.4% | -65.5% | -94.6% | -257.1% | -291.3% | -267.3% | -220.6% | -228.4% | -319.8% | -192.7% | -213.0% | -186.8% | -305.0% | -227.2% | -255.4% | -188.5% | -135.4% | -169.2% | -176.5% |
| — | +93.4% | +99.9% | +75.5% | +57.1% | -12.6% | +8.9% | -38.7% | -3.6% | -22.3% | -4.9% | +15.2% | +16.6% | +0.9% | -125.2% | -34.3% | -44.7% | +14.9% | +30.6% | +18.9% | +22.7% | |
| Net Margin | -210.5% | -19.1% | -3.1% | -53.5% | -124.5% | -260.0% | -299.5% | -276.4% | -225.5% | -236.0% | -332.8% | -208.1% | -222.3% | -201.0% | -317.0% | -245.0% | -270.0% | -193.6% | -146.6% | -178.2% | -201.3% |
| — | +92.6% | +99.0% | +80.7% | +44.8% | -10.1% | +10.0% | -32.9% | -1.4% | -17.4% | -5.0% | +15.1% | +17.7% | -3.8% | -116.2% | -37.5% | -34.1% | +19.7% | +43.3% | +21.8% | +18.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -249.3% | -13.5% | -1.8% | -22.7% | -39.0% | -33.7% | -47.7% | -133.4% | -61.3% | -84.5% | -774.4% | — | — | — | — | -738.0% | -552.2% | -1836.5% | -116.6% | -35.7% | -24.7% |
| — | +59.9% | +96.2% | +83.0% | +36.4% | +60.1% | +93.8% | — | — | — | — | — | — | — | — | -1968.2% | -2137.0% | -8339.2% | -263.9% | +7.0% | +23.6% | |
| ROA | -59.5% | -4.6% | -0.6% | -7.5% | -14.2% | -15.3% | -15.0% | -13.4% | -11.6% | -11.4% | -20.2% | -12.6% | -14.0% | -11.5% | -16.6% | -10.1% | -12.1% | -12.8% | -8.7% | -7.9% | -8.8% |
| — | +69.7% | +95.8% | +43.8% | -23.0% | -33.9% | +25.8% | -6.2% | +17.6% | +0.7% | -22.3% | -25.4% | -16.0% | +10.2% | -91.0% | -27.5% | -36.6% | -44.4% | +29.0% | +35.9% | +29.2% | |
| ROIC | -86.5% | -7.2% | -0.1% | -16.1% | -15.9% | -26.6% | -27.4% | -18.2% | -15.5% | -23.6% | -90.0% | -25.4% | -27.6% | -26.4% | -59.9% | -61.2% | -39.4% | -22.7% | -14.7% | -18.1% | -26.3% |
| — | +72.9% | +99.5% | +11.4% | -2.7% | -12.7% | +69.6% | +28.6% | +43.9% | +10.6% | -50.3% | +58.5% | +29.9% | -16.2% | -306.3% | -239.2% | -49.8% | +33.5% | +56.1% | +50.1% | +41.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.04 | 1.02 | 0.77 | 1.06 | 1.04 | 0.79 | 0.59 | 13.21 | 4.60 | 2.41 | 35.53 | — | — | — | — | — | 13.39 | — | 18.77 | 6.98 | 1.49 |
| — | +29.5% | +28.7% | -92.0% | -77.4% | -67.3% | -98.3% | — | — | — | — | — | — | — | — | — | +797.8% | — | +1580.2% | +245.1% | +1.6% | |
| Debt / EBITDA | — | — | 156.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.83 | 2.86 | 3.72 | 4.47 | 3.83 | 4.63 | 6.68 | 5.86 | 5.45 | 6.37 | 2.71 | 1.80 | 4.12 | 4.71 | 5.15 | 6.01 | 6.69 | 4.59 | 5.93 | 6.04 | 6.19 |
| — | -38.2% | -44.2% | -23.8% | -29.8% | -27.3% | +146.8% | +225.2% | +32.4% | +35.1% | -47.5% | -70.0% | -38.5% | +2.6% | -13.1% | -0.5% | +8.1% | -46.1% | -43.1% | -1.9% | +18.1% | |
| Quick Ratio | 3.54 | 2.59 | 3.40 | 4.10 | 3.54 | 4.34 | 6.33 | 5.44 | 5.12 | 5.99 | 2.53 | 1.61 | 3.75 | 4.31 | 4.77 | 5.63 | 6.33 | 4.11 | 5.34 | 5.52 | 5.70 |
| — | -40.4% | -46.3% | -24.7% | -30.8% | -27.5% | +149.9% | +238.9% | +36.6% | +38.8% | -46.9% | -71.5% | -40.7% | +4.9% | -10.6% | +1.8% | +11.0% | -48.1% | -45.6% | +0.2% | +18.1% | |
| Interest Coverage | -14.18 | -3.78 | 0.44 | -7.07 | -14.94 | -17.16 | -14.16 | -10.94 | -9.95 | -9.46 | -13.15 | -6.49 | -7.95 | -6.86 | -10.93 | -7.05 | -8.97 | -38.25 | -27.59 | -27.88 | -9.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INSM stock.
Insmed Incorporated's current P/E is -41.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Insmed Incorporated's current operating margin is -194.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Insmed Incorporated's business trajectory between earnings reports.